芯片股快速拉昇 製造關鍵設備再突破 離子注入機實現全譜系產品國產化
格隆匯3月17日丨芯片股快速拉昇,韋爾股份、紫光國微漲超5%,兆易創新、富瀚微、卓勝微等漲勢進一步擴大。芯片製造關鍵設備再突破,離子注入機實現全譜系產品國產化。中國電子科技集團有限公司今日對外公佈,該集團旗下裝備子集團攻克系列“卡脖子”技術,已成功實現離子注入機全譜系產品國產化,包括中束流、大束流、高能、特種應用及第三代半導體等離子注入機,工藝段覆蓋至28nm,為我國芯片製造產業鏈補上重要一環,為全球芯片製造企業提供離子注入機一站式解決方案。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.